Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
OGEN 
Oragenics Inc (OGEN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: OGEN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $2
1 Year Target Price $2
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -55.99% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 5.37M USD | Price to earnings Ratio - | 1Y Target Price 2 |
Price to earnings Ratio - | 1Y Target Price 2 | ||
Volume (30-day avg) 1 | Beta 0.82 | 52 Weeks Range 1.01 - 15.60 | Updated Date 09/16/2025 |
52 Weeks Range 1.01 - 15.60 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -19.51 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -245.73% | Return on Equity (TTM) -748.05% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 6391579 | Price to Sales(TTM) 89.28 |
Enterprise Value 6391579 | Price to Sales(TTM) 89.28 | ||
Enterprise Value to Revenue 105.83 | Enterprise Value to EBITDA 0.21 | Shares Outstanding 4127170 | Shares Floating 4027543 |
Shares Outstanding 4127170 | Shares Floating 4027543 | ||
Percent Insiders 2.41 | Percent Institutions 2.56 |
Upturn AI SWOT
Oragenics Inc
Company Overview
History and Background
Oragenics, Inc. (OGEN) is a biotechnology company focused on developing novel antibiotics to address emerging bacterial resistance and vaccines to combat infectious diseases. It was founded in 1996 and has evolved through various phases of research and development.
Core Business Areas
- Antibiotics Development: Development of novel antibiotics using the lantibiotics platform, particularly aimed at combating multi-drug resistant organisms.
- Vaccine Development: Development of Terra CoV-2 vaccine platform, focusing on COVID-19 and potentially other infectious diseases. This program was discontinued.
Leadership and Structure
The leadership team consists of the CEO, CFO, and other key executives responsible for strategic direction, financial management, and research and development. The organizational structure includes departments for research, clinical development, and regulatory affairs.
Top Products and Market Share
Key Offerings
- AG013: An investigational oral biotherapeutic for the prevention of oral mucositis in cancer patients. Currently in development. There is no current market share data or revenue. Competitors include Soligenix (SNGX) and Galera Therapeutics (GRTX).
- Lantibiotics platform: Developing novel antibiotics targeting multi-drug resistant organisms. No revenue yet. Competitors are larger pharmaceutical companies with antibiotic development programs.
Market Dynamics
Industry Overview
The biotechnology industry is characterized by intense research and development, regulatory hurdles, and significant investment requirements. The demand for novel antibiotics is increasing due to the rise of antibiotic-resistant bacteria, also the demand for COVID-19 vaccines are high.
Positioning
Oragenics is positioned as a company focusing on addressing unmet needs in the area of infectious diseases. Its lantibiotics platform provides a competitive advantage in developing novel antibiotics. Discontinued the Terra CoV-2 vaccine.
Total Addressable Market (TAM)
The global antibiotics market and the global vaccines market are both multi-billion dollar markets. Oragenics aims to capture a portion of this TAM with its product candidates. Oragenics' success depends on clinical trial outcomes and regulatory approvals.
Upturn SWOT Analysis
Strengths
- Novel lantibiotics platform for antibiotic development
- Focus on addressing unmet needs in infectious diseases
- Experienced management team
Weaknesses
- Limited financial resources
- Dependence on clinical trial success and regulatory approvals
- High risk associated with biotechnology research and development
- Has discontinued several trials/products in the past.
Opportunities
- Partnerships with larger pharmaceutical companies
- Government funding for antibiotic development
- Expanding the application of the lantibiotics platform
- Increase in COVID vaccine demand due to global threat
Threats
- Competition from larger pharmaceutical companies
- Clinical trial failures
- Regulatory hurdles
- Changes in the healthcare landscape
Competitors and Market Share
Key Competitors
- Soligenix (SNGX)
- Galera Therapeutics (GRTX)
- Larger pharmaceutical companies
Competitive Landscape
Oragenics competes with larger pharmaceutical and biotechnology companies. Its advantages lie in its innovative lantibiotics platform and focus on addressing unmet needs. However, it faces challenges due to its limited financial resources and dependence on clinical trial success.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been characterized by research and development progress and financial performance, with periods of volatility.
Future Projections: Future growth is dependent on clinical trial outcomes, regulatory approvals, and potential partnerships. Analyst estimates vary depending on the success of their products.
Recent Initiatives: Recent strategic initiatives include advancing clinical trials, seeking partnerships, and optimizing its cost structure.
Summary
Oragenics is a biotechnology company focused on novel antibiotic development and, in the past, vaccine development. The company's strengths lie in its lantibiotics platform. Oragenics faces challenges due to limited resources, regulatory hurdles, and clinical trial risks. Future success hinges on clinical trial progress and partnerships.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered investment advice. Investment decisions should be based on individual research and consultation with a financial professional.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Oragenics Inc
Exchange NYSE MKT | Headquaters Sarasota, FL, United States | ||
IPO Launch date 2004-02-25 | CEO, President, CFO, Secretary & Treasurer Ms. Janet Huffman | ||
Sector Healthcare | Industry Biotechnology | Full time employees 3 | Website https://www.oragenics.com |
Full time employees 3 | Website https://www.oragenics.com | ||
Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases in the United States. Its lead product is ONP-002 for the treatment of mild traumatic brain injury, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The company also develops NT-CoV2-1, a SARS-CoV-2 vaccine product candidate; and lantibiotics. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Sarasota, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.